02.25.19

Eyenovia Announces Confirmatory Results from Second MicroStat Phase 3 Registration Study for Mydriasis

Source: Eyenovia

02.13.19

Eyenovia Confirms Expanded MicroProst Phase 3 Indication to Enroll Broad Patient Population for IOP Lowering

Source: Eyenovia

02.06.19

Eyenovia Announces FDA Acceptance of IND Application for MicroPine

Source: Eyenovia

01.30.19

Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase 3 Registration Study for Mydriasis

Source: Eyenovia

12.04.18

Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study

Source: Eyenovia

11.28.18

Eyenovia Publishes PG21 Phase 2 Trial Results Examining IOP Lowering Effect and Patient Usability

Source: Eyenovia

11.26.18

Eyenovia Initiates Phase 3 MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study

Source: Eyenovia

11.13.18

Eyenovia Announces FDA Acceptance of MicroStat IND Application for Mydriasis

Source: Eyenovia

08.13.18

Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates IOP Lowering and Patient Usability

Source: Eyenovia

07.09.18

Eyenovia Appoints Michael Rowe as Vice President of Marketing

Source: Eyenovia

View more stories